A practical reference on GIP receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-08. Anything still debated is marked as such rather than presented as settled.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
纯度评估通常综合反相色谱、体积排阻色谱与质谱三方面信息：前者反映疏水性杂质，后者反映聚集体，质谱则确认分子量与主要降解产物。有关降解途径的完整图谱——例如脱酰胺、氧化与水解各占多大比例——在不同储存条件下仍有差异，属于需要逐案验证的问题。
质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持，单次测定不足以判定批次的稳定性。实验室之间方法转移时，色谱柱品牌与梯度差异常导致保留时间漂移，因此方法验证十分必要。
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Free base form |
| Molecular mass | Approximately 4813 Da | Calculated from the sequence |
| Amino acid residues | 39 | GIP-derived backbone |
| Receptor targets | GIP and GLP-1 | Dual agonist |
| Circulating half-life | About 5 days | Supports weekly administration |
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
===== Supporters ===== Two stags Or attired and unguled Azure each gorged with a collar of braid Gules Argent and Azure standing upon a representation of the Scarborough Bluffs proper rising above the waters of Lake Ontario Azure and Argent;
May 21, 1992: Decree concerning the responsibilities of the Secretary of State for Women's Rights and Consumer Affairs. July 22, 1992: Law reforming the provisions of the Penal Code relating to the repression of crimes and offenses against persons. November 2, 1992: Law concerning abuse of authority in sexual matters in work relationships and amending the Labour Code and the Code of Criminal Procedure. January 8, 1992: Law amending the Civil Code concerning civil status, family, and children's rights, and establishing the family affairs judge. January 27, 1993: Law concerning various social measures, notably establishing the offense of obstructing abortion and decriminalizing self-induced abortion. April 8, 1993: Decree concerning the responsibilities of the Minister of State, Minister of Social Affairs, Health, and the City. July 22, 1993: Law reforming nationality law. August 2, 1993: Law concerning the control of immigration and the conditions of entry, reception, and residence of foreigners in France. April 21, 1994: Discussion on the possibility of quotas and potential gender parity in the exercise of responsibilities, particularly political ones. July 15, 1994: Law concerning the family. July 29, 1994: Law concerning respect for the human body. July 29, 1994: Law concerning the donation and use of elements and products of the human body, medically assisted procreation, and prenatal diagnosis. June 1, 1995: Decree concerning the responsibilities of the Minister for Intergenerational Solidarity. October 18, 1995: Creation of the Observatory for Gender Parity.
Forequarter Neck – neck chops Shoulder – shoulder chops, shoulder roast (usually boned and rolled) Rib-eye Breast Knuckle Loin Rib-loin – racks, frenched cutlets, spare ribs Mid-loin – striploin (backstrap), loin chops Tenderloin Flap Full leg – leg roast (may be boned and rolled), leg chops. A short-cut leg is a full leg without the chump; a carvery leg is a short-cut leg without the thick flank Chump (rump) – chump chops, rump steak Thick flank (knuckle) – schnitzel Topside & silverside – steaks Shank
Sources: en.wikipedia.org
After harnessing fire, humans discovered other forms of energy. The earliest known use of wind power is the sailing ship; the earliest record of a ship under sail is that of a Nile boat dating to around 7,000 BCE. From prehistoric times, Egyptians likely used the power of the annual flooding of the Nile to irrigate their lands, gradually learning to regulate much of it through purposely built irrigation channels and "catch" basins. The ancient Sumerians in Mesopotamia used a complex system of canals and levees to divert water from the Tigris and Euphrates rivers for irrigation. Archaeologists estimate that the wheel was invented independently and concurrently in Mesopotamia (in present-day Iraq), the Northern Caucasus (Maykop culture), and Central Europe. Time estimates range from 5,500 to 3,000 BCE, with most experts putting it closer to 4,000 BCE. The oldest artifacts with drawings depicting wheeled carts date from about 3,500 BCE. More recently, the oldest-known wooden wheel in the world as of 2024 was found in the Ljubljana Marsh of Slovenia; Austrian experts have established that the wheel is between 5,100 and 5,350 years old. The invention of the wheel revolutionized trade and war. It did not take long to discover that wheeled wagons could be used to carry heavy loads. The ancient Sumerians used a potter's wheel and may have invented it. A stone pottery wheel found in the city-state of Ur dates to around 3,429 BCE, and even older fragments of wheel-thrown pottery have been found in the same area.
The relationship between the Druze and Christians in Israel has generally been marked by harmony and peaceful coexistence, with both communities living together in peace, harmony, and friendship. However, there have been rare clashes, including instances of violence by the Druze against Christians, such as the incident in 2005 in the town of town of Maghar. Druze and Christians in Israel participate in each other's cultural events, including births, weddings, funerals, and celebrations like the Christian festival of Mar Ilyas (Saint Elias) in Haifa. Additionally, many Druze students are enrolled in Christian schools across the Galilee and Haifa regions. Some Druze towns are situated near significant Christian holy sites, with the most prominent being the Catholic Muhraqa Monastery located 2 kilometres southeast of Daliyat al-Karmel, the largest Druze town in Israel, and marks the contest between prophet Elijah and the priests of Ba'al. It belongs to the Carmelite Order. In the predominantly Druze town of Hurfeish, there is the Church and House of Saint Mariam Baouardy. Interaction between Christians, including members of the Maronite, Eastern Orthodox, Melkite, and other churches, and the Unitarian Druze has resulted in the establishment of mixed villages and towns in Galilee region, Mount Carmel, and the Israeli-occupied portion of the Golan Heights. These include Abu Snan, Daliyat al-Karmel, Ein Qiniyye, Hurfeish, Isfiya, Kafr Yasif, Kisra-Sumei, Majdal Shams, Maghar, Peki'in, Rameh and Shefa-Amr, where more than 82,000 Druze and 30,000 Christians reside together.
In 1997, the FDA proposed a rule to require pediatric drug trials from the sponsors of New Drug Applications. However, this new rule was successfully preempted in federal court as exceeding the FDA's statutory authority. While this debate was unfolding, Congress used the Food and Drug Administration Modernization Act of 1997 to pass incentives that gave pharmaceutical manufacturers a six-month patent term extension on new drugs submitted with pediatric trial data. The Best Pharmaceuticals for Children Act of 2007 reauthorized these provisions and allowed the FDA to request NIH-sponsored testing for pediatric drug testing, although these requests are subject to NIH funding constraints. In the Pediatric Research Equity Act of 2003, Congress codified the FDA's authority to mandate manufacturer-sponsored pediatric drug trials for certain drugs as a "last resort" if incentives and publicly funded mechanisms proved inadequate.
==== EPS in building construction ==== Sheets of EPS are commonly packaged as rigid panels (common in Europe is a size of 100 cm x 50 cm, usually depending on an intended type of connection and glue techniques, it is, in fact, 99.5 cm x 49.5 cm or 98 cm x 48 cm; less common is 120 x 60 cm; size 4 by 8 ft (1.2 by 2.4 m) or 2 by 8 ft (0.61 by 2.44 m) in the United States). Common thicknesses are from 10 mm to 500 mm. Many customizations, additives, and thin additional external layers on one or both sides are often added to help with various properties. An example of this is lamination with cement board to form a structural insulated panel. Thermal conductivity is measured according to EN 12667. Typical values range from 0.032 to 0.038 W/(m⋅K) depending on the density of the EPS board. The value of 0.038 W/(m⋅K) was obtained at 15 kg/m3 while the value of 0.032 W/(m⋅K) was obtained at 40 kg/m3 according to the datasheet of K-710 from StyroChem Finland. Adding fillers (graphites, aluminum, or carbons) has allowed the thermal conductivity of EPS to reach around 0.030–0.034 W/(m⋅K) (as low as 0.029 W/(m⋅K)) and as such has a grey/black color which distinguishes it from standard EPS. Several EPS producers have produced a variety of these increased thermal resistance EPS usage for this product in the UK and EU. Water vapor diffusion resistance (μ) of EPS is around 30–70. ICC-ES (International Code Council Evaluation Service) requires EPS boards used in building construction meet ASTM C578 requirements.
Sources: en.wikipedia.org
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.
A fatty diacid side chain promotes binding to albumin, which delays clearance from circulation. The half-life of roughly five days makes a weekly schedule practical.
No. It is a synthetic peptide whose backbone is based on the natural incretin hormone GIP. Non-natural residues and the lipid side chain were engineered to improve stability and duration of action.
建议在低温、避光、干燥环境中密封保存，常见条件为 2 至 8 摄氏度，长期存放可置于更低温度。应避免反复冻融，并尽量减少容器开启次数。